⌘K
t
| TIDM | CIZ |
| Share Price | Loading... |
| Market Cap | Loading... |
Cizzle Biotechnology Holdings plc announced on 30 April 2026 the publication of its Annual Report and Financial Statements for the year ended 31 December 2025. The Annual Report is available via a specified RNS-provided PDF link and will also be available on the National Storage Mechanism and the Company's website.
| Date | 30 Apr 2026 |
| Time | 07:00:06 |
| Category | Results |
| ID | 4787C |
30 April 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Final results for the year ended 31 December 2025
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2025 (the "Annual Report").
The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: https://cizzlebiotechnology.com
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale (Corporate Finance) |
|
|
Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6632 |
|
Tim Metcalfe |
|
|
Florence Staton |
|
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.